Submodule
Targets and Clinical Role
Apixaban, rivaroxaban, and edoxaban directly inhibit factor Xa, while dabigatran directly inhibits thrombin after conversion from dabigatran etexilate.
- Factor Xa and thrombin targets
- Rapid onset and offset
- DOAC-eligible indications
- Situations requiring another strategy
Reduce prothrombinase output
Reduce fibrin formation and amplification
Adherence determines continuity
Do not treat products as interchangeable
Interrupt coagulation at a defined target
Factor Xa converts prothrombin to thrombin within the prothrombinase complex. Apixaban, rivaroxaban, and edoxaban reduce thrombin generation by directly inhibiting factor Xa. Dabigatran inhibits thrombin, reducing fibrin formation and thrombin-mediated amplification.
Respect rapid onset and finite persistence
DOACs begin working within hours and do not need routine INR-guided titration. Their anticoagulant effect also declines more quickly than warfarin after interruption. This simplifies initiation but makes adherence, last-dose history, kidney function, and access central safety variables.
Use indication-specific evidence
DOACs are preferred for many eligible patients with nonvalvular atrial fibrillation or VTE. Product approval does not make doses interchangeable. Each indication has its own treatment phase, renal criteria, interaction rules, and duration decision.
Recognize when a DOAC is not the answer
Mechanical prosthetic valves require vitamin K antagonist therapy. Moderate or severe rheumatic mitral stenosis with atrial fibrillation also favors warfarin. Pregnancy, severe organ dysfunction, important interactions, unreliable access, major absorption concerns, and selected thrombophilias require individualized specialist review.
Quick check
Submodule
Oral Factor Xa Inhibitor Regimens
Apixaban, rivaroxaban, and edoxaban share a target, but their atrial fibrillation, VTE, food, kidney, weight, and initiation rules are product specific.
- Apixaban criteria and VTE phases
- Rivaroxaban food and phase rules
- Edoxaban renal boundaries
- Dose verification workflow
AF criteria differ from VTE phases
15 and 20 mg require food
High CrCl restriction in NVAF
Recalculate at every transition
Separate apixaban AF criteria from VTE phases
For nonvalvular atrial fibrillation, apixaban dose reduction follows the labeled combination of age, body weight, and serum creatinine criteria. Acute VTE instead uses a higher twice-daily initial phase followed by a standard twice-daily treatment phase, with a lower twice-daily dose used only for extended recurrence reduction after initial therapy. Do not import AF reduction criteria into acute VTE treatment.
Pair rivaroxaban dose with food and phase
Rivaroxaban nonvalvular atrial fibrillation dosing uses creatinine clearance and is taken with the evening meal. Acute VTE uses 15 mg twice daily with food for 21 days, followed by 20 mg once daily with food. A 10 mg once-daily extended option can follow at least six months of standard anticoagulation. The 15 mg and 20 mg tablets require food for reliable exposure.
Apply edoxaban boundaries exactly
Edoxaban should not be used for nonvalvular atrial fibrillation when creatinine clearance is above 95 mL/min because of reduced efficacy. Adult VTE treatment begins only after 5 to 10 days of parenteral anticoagulation. The VTE dose is reduced for creatinine clearance 15 to 50 mL/min, body weight at or below 60 kg, or specified P-gp inhibitors.
Recalculate rather than copy
Verify the labeled renal method, actual body weight when required, current creatinine, indication, treatment day, age, weight, liver function, interacting drugs, and adherence. A prior correct dose can become wrong after weight change, acute kidney injury, recovery, a new inhibitor, or a phase transition.
Quick check
Submodule
Dabigatran Pharmacology and Use
Dabigatran etexilate is an oral prodrug whose active metabolite directly inhibits thrombin and whose safe use depends heavily on kidney function, P-gp, and product handling.
- Prodrug activation and thrombin inhibition
- Renal elimination and P-gp
- VTE lead-in
- Capsule handling and GI tolerability
Swallow whole and protect from moisture
Produce direct thrombin inhibitor
Reassess during acute illness
Use for emergency surgery or uncontrolled major bleeding
Convert the prodrug to the active inhibitor
Dabigatran etexilate is converted by esterases to dabigatran. The active drug binds thrombin and reduces conversion of fibrinogen to fibrin as well as thrombin-driven amplification. It does not require CYP-mediated activation.
Pair renal function with P-gp exposure
Renal impairment and P-gp inhibition can each increase dabigatran exposure, and their effects can compound. Reassess kidney function during dehydration, infection, hospitalization, or other acute change. Avoid strong P-gp induction because it can reduce exposure and protection.
Use the correct initiation pathway
For adult DVT and PE treatment, dabigatran begins after 5 to 10 days of parenteral anticoagulation. This differs from apixaban and rivaroxaban acute VTE regimens, which contain oral intensified initial phases.
Protect the dosage form
Dabigatran capsules should be swallowed whole and stored according to the product instructions to protect them from moisture. Opening, crushing, or chewing a capsule can substantially increase exposure. Dyspepsia is common and should be distinguished from occult or overt gastrointestinal bleeding.
Quick check
Submodule
Selection, Interactions, and Implementation
A DOAC plan succeeds only when the selected product fits organ function, interacting drugs, absorption, adherence, dosage-form needs, access, and the clinical indication.
- Creatinine clearance and hepatic function
- P-gp and CYP3A interactions
- Adherence and missed doses
- Absorption and access
Apply the correct regimen
Use product-specified renal criteria
Predict exposure and bleeding
Prevent missed or ineffective doses
Assess organ function using the product standard
Use the renal estimate specified in labeling and review the trajectory, not just one result. Acute kidney injury can cause accumulation, while recovery can remove a dose-reduction criterion. Significant hepatic disease can alter coagulation and drug handling and may make a DOAC inappropriate.
Map transport and metabolism
All four agents interact with P-gp to clinically relevant degrees, while apixaban and rivaroxaban also depend importantly on CYP3A4. Combined strong P-gp and CYP3A4 inhibitors can raise factor Xa inhibitor exposure, and strong dual inducers can lower it. Product-specific instructions determine dose reduction or avoidance.
Make adherence clinically concrete
Premature discontinuation increases thrombotic risk. Teach the exact missed-dose instruction for the product and schedule rather than using one universal rule. Ask about routine, pill organization, refills, cost, travel, swallowing, and the consequences of a missed dose.
Account for delivery and absorption
Food requirements, bariatric or major gastrointestinal surgery, feeding tubes, dysphagia, vomiting, malabsorption, and dosage-form manipulation can change exposure or feasibility. Select a product and route with evidence for the patient's anatomy and administration pathway.
Quick check
Submodule
Monitoring, Procedures, and Transitions
DOACs do not use routine INR titration, yet they require longitudinal organ surveillance, adherence review, procedure planning, last-dose reconstruction, and product-aware laboratory interpretation.
- CBC and organ surveillance
- Drug-sensitive laboratory testing
- Procedure and neuraxial interruption
- Transitions and resumption
Reassess at clinically appropriate intervals
Do not rely on normal PT or aPTT alone
Use product and organ-specific timing
Avoid an unnecessary unprotected interval
Monitor without routine dose titration
Periodic CBC, kidney and liver assessment, bleeding and thrombosis review, adherence, interactions, procedures, and access replace routine INR titration. Increase surveillance when age, organ function, illness, or medication changes make exposure less predictable.
Interpret assays by drug and reagent
A normal PT, INR, or aPTT cannot reliably exclude clinically important exposure to every DOAC. Drug-calibrated anti-Xa assays can assess apixaban, rivaroxaban, or edoxaban exposure when available. Thrombin-sensitive testing is more useful for dabigatran. Results require timing and assay context.
Plan interruption around residual effect
Procedure bleeding risk, drug, dose, renal clearance, last dose, urgency, and hemostasis determine interruption. Neuraxial procedures and catheters require especially strict product-specific timing and neurologic surveillance because spinal hematoma can cause permanent injury.
Use explicit transitions and restart plans
Transitions among DOACs, warfarin, and parenteral anticoagulants need exact stop and start times. Some DOACs affect INR during warfarin conversion. After a procedure or bleeding event, restart timing balances achieved hemostasis against the untreated thrombotic indication.
Quick check
Submodule
Major Bleeding and Reversal
Severe DOAC bleeding requires immediate stabilization and source control, exposure assessment, agent-matched reversal or hemostatic support, and a deliberate plan to restore anticoagulation.
- Bleeding severity and source control
- Idarucizumab
- Factor Xa inhibitor reversal
- Thrombosis risk and resumption
Estimate residual effect
Do not delay definitive hemostasis
Match the confirmed agent
Resume as soon as medically appropriate
Stabilize before perfect certainty
Stop ongoing exposure, assess airway and circulation, obtain targeted laboratories and imaging, transfuse when indicated, and control the source. Drug, dose, last administration, renal and hepatic function, interacting agents, and site help estimate residual effect and urgency.
Reverse dabigatran specifically
Idarucizumab binds dabigatran and is indicated when reversal is needed for emergency surgery or urgent procedures or for life-threatening or uncontrolled bleeding. Continue supportive care and source control, and evaluate for recurrent anticoagulant effect when clinically relevant.
Match factor Xa reversal to the agent and setting
Andexanet is labeled for life-threatening or uncontrolled bleeding associated with apixaban or rivaroxaban. Institutions may use prothrombin complex concentrate in selected factor Xa inhibitor bleeding pathways. Follow current labeling, local protocol, availability, and specialist guidance rather than assuming every approach is equivalent.
Restore protection when medically appropriate
Reversal and interruption expose the patient to the original thrombotic disease and can add treatment-related thrombosis risk. Reassess hemostasis, bleeding source, procedure status, indication, and thrombosis risk repeatedly so anticoagulation resumes as soon as it is medically appropriate.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 104 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- DailyMed. Apixaban Prescribing Information
- DailyMed. Rivaroxaban Prescribing Information
- DailyMed. Edoxaban Prescribing Information
- DailyMed. Dabigatran Etexilate Prescribing Information
- DailyMed. Idarucizumab Prescribing Information
- DailyMed. Andexanet Alfa Prescribing Information
- American Heart Association and American College of Cardiology. 2026 Acute Pulmonary Embolism Guideline